ClinicalTrials.gg
CompletedNCT02513303ACCESSUpdated Oct 9, 2025Results posted

Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes

A Phase 3 interventional study of Sirolimus and AV Fistula Surgery in Complication of Renal Dialysis, End Stage Renal Disease and End Stage Kidney Disease, sponsored by Vascular Therapies, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Vascular Therapies, Inc. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
269
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing sirolimus in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Sirolimus · Kidney Failure, Chronic.

Enrollment
3rd of 12
269 · median 80
Started
2015
the only one that year
Phase 3
3 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
2 of 12
Vascular Therapies, Inc.

Among the 12 studies testing sirolimus in Kidney Failure, Chronic, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 3 in phase 3, and was the 11th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies testing sirolimus in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing sirolimus in Kidney Failure, Chronic as a file.
02

Study summary

The objective of this study is to evaluate efficacy and safety outcomes following use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV fistula for vascular access (index procedure).

Read the detailed description

The objective of this study is to evaluate efficacy and safety outcomes following use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV fistula for vascular access (index procedure). Following successful creation of the AV fistula, the cohort randomized to the treatment group will receive the SeCI; the control group will not receive an implant. The primary hypothesis is that the proportion of subjects that meet requirements for fistula suitability for dialysis six months following the index procedure will be higher in the treatment group in comparison to the control group.

03

Conditions studied

  • Complication of Renal Dialysis
  • End Stage Renal Disease
  • End Stage Kidney Disease
  • ESRD
  • Chronic Kidney Failure
  • Complication of Hemodialysis
  • Vascular Access Complication
  • Arteriovenous Fistula

Keywords

  • Dialysis
  • End Stage Renal Disease
  • End Stage Kidney Disease
  • ESRD
  • Chronic Kidney Failure
  • Chronic Renal Failure
  • Chronic Kidney Disease
  • Hemodialysis
  • Vascular Access
  • Arteriovenous Fistula
  • AV Fistula
  • AVF
  • Nephrology
  • Vascular Surgery
  • Dialysis Access
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently on hemodialysis for ≤12 months or expected to initiate hemodialysis within approximately 6 months of the creation of the AV fistula.
  • Vascular anatomy suitable for creation of the AV fistula, determined by pre procedure duplex ultrasound
  • Successful creation of a single stage radiocephalic or brachiocephalic end to side fistula

Exclusion criteria

Exclusion Criteria:

  • Prior AV access created on the limb where the fistula surgery is planned
  • ST-elevation MI or cerebrovascular accident within 30 days of the index procedure
  • Known to the following: sirolimus, beef or bovine collagen
  • Hypotension with systolic blood pressures \<100 mm Hg at the time of screening
  • Known or suspected active infection at the time of the AV fistula surgery
  • Known to be positive
  • Prisoner, mentally incompetent, and/or alcohol or drug abuser
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    Treatment Group

    AV fistula surgery Single administration of sirolimus-eluting Collagen implant

    Drug: Sirolimus · Procedure: AV Fistula Surgery · Device: Sirolimus-eluting Collagen Implant (SeCI)

  • Other
    Control Group

    AV fistula surgery

    Procedure: AV Fistula Surgery

Interventions

  • A single dose of sirolimus delivered locally

    Also known as: Rapamycin

  • ProcedureAV Fistula Surgery

    AV Fistula Surgery

  • DeviceSirolimus-eluting Collagen Implant (SeCI)

    SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.

    Also known as: Rapamycin

06

What researchers measure

Primary outcomes

  1. Fistula Suitability for Dialysis at 6 Months (FSD6)

    For subjects who are on hemodialysis by day 150, suitability for dialysis will be determined by the ability to use the fistula for dialysis using 2-needles with a mean dialysis machine blood pump speed of ≥300 mL/min for two-thirds of the dialysis sessions during a 30 day suitability ascertainment period that begins 150 days after fistula creation. For subjects who are not on hemodialysis on day of enrollment and who do not initiate hemodialysis by day 150, suitability for dialysis will be determined by a vascular ultrasound performed at the 6 month follow up visit. Suitability for dialysis will be defined as a fistula with an access vein diameter (AVD) of ≥6 mm (internal diameter) and an access blood flow of ≥500 mL/min.

    Time frame: 6 months

07

Results

Posted Oct 9, 2025

Participant flow

Participant flow — Overall Study
MilestoneSirogenControlRun-in
Started12511826
Completed10510122
Not completed20174
Withdrew: Withdrawal by subject972
Withdrew: Lost to follow-up240
Withdrew: Adverse event010
Withdrew: Physician decision110
Withdrew: Death842

Outcome measures

PrimaryFistula Suitability for Dialysis at 6 Months (FSD6)

For subjects who are on hemodialysis by day 150, suitability for dialysis will be determined by the ability to use the fistula for dialysis using 2-needles with a mean dialysis machine blood pump speed of ≥300 mL/min for two-thirds of the dialysis sessions during a 30 day suitability ascertainment period that begins 150 days after fistula creation. For subjects who are not on hemodialysis on day of enrollment and who do not initiate hemodialysis by day 150, suitability for dialysis will be determined by a vascular ultrasound performed at the 6 month follow up visit. Suitability for dialysis will be defined as a fistula with an access vein diameter (AVD) of ≥6 mm (internal diameter) and an access blood flow of ≥500 mL/min.

Time frame:
6 months
Reported as:
Count of participants · Participants
Fistula Suitability for Dialysis at 6 Months (FSD6)
ParticipantsSirogenControlRun-in
Met FSD6 criteria747621
Did not meet FSD6 criteria43355
Indeterminant FSD6870
Statistical analysis
  • Sirogen vs Control · Regression, Logistic · p = 0.2942

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sirogen8/127 (6.3%)56/127 (44.1%)115/127 (90.6%)
Control4/116 (3.4%)55/116 (47.4%)101/116 (87.1%)
Run-in2/26 (7.7%)15/26 (57.7%)24/26 (92.3%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventSirogenControlRun-in
SepsisInfections and infestations1/1271/1163/26
SyncopeNervous system disorders1/1270/1163/26
End stage renal diseaseRenal and urinary disorders2/1275/1163/26
Pleural effusionRespiratory, thoracic and mediastinal disorders3/1272/1163/26
Cardiac arrestCardiac disorders3/1270/1162/26
Fluid overloadMetabolism and nutrition disorders3/1275/1162/26
HyperkalaemiaMetabolism and nutrition disorders2/1276/1162/26
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1270/1162/26
Cardiac failure congestiveCardiac disorders7/1273/1160/26
PneumoniaInfections and infestations6/1276/1160/26
Most frequent other events
Showing 10 of 17
Most frequent other events
EventSirogenControlRun-in
Arteriovenous fistula site complicationInjury, poisoning and procedural complications71/12759/11614/26
Haemodialysis complicationInjury, poisoning and procedural complications41/12735/1166/26
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications17/12718/1166/26
Arteriovenous fistula occlusionInjury, poisoning and procedural complications3/1277/1164/26
ConstipationGastrointestinal disorders1/1271/1163/26
Muscle spasmsMusculoskeletal and connective tissue disorders2/1272/1163/26
Haemodialysis-induced symptomInjury, poisoning and procedural complications11/1276/1161/26
Vision blurredEye disorders0/1270/1162/26
Abdominal painGastrointestinal disorders3/1271/1162/26
Fluid overloadMetabolism and nutrition disorders1/1270/1162/26

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SirogenControlRun-inTotal
<=18 years0000
Between 18 and 65 years748213169
>=65 years513613100
Age, Continuous
Age, Continuous(years)SirogenControlRun-inTotal
Mean59.7 ± 14.957.7 ± 13.961.4 ± 17.359.0 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)SirogenControlRun-inTotal
Female2823657
Male979520212
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SirogenControlRun-inTotal
American Indian or Alaska Native0011
Asian83112
Native Hawaiian or Other Pacific Islander1012
Black or African American3130869
White848115180
More than one race0000
Unknown or Not Reported1405
Region of Enrollment
Region of Enrollment(participants)SirogenControlRun-inTotal
United States12511826269
Kidney Disease Status at Enrollment
Kidney Disease Status at Enrollment(Participants)SirogenControlRun-inTotal
Chronic kidney disease3336170
End stage renal disease928225199
08

Study locations

4 sites
  • Nephrology Consultants, LLC
    Huntsville, Alabama 35805, United States
  • AKDHC Medical Research Service
    Phoenix, Arizona 85012, United States
  • San Diego Institute of Medical Research
    Escondido, California 92025, United States
  • Northeast Clinical Research Center
    Bethlehem, Pennsylvania 18017, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Jun 2021 and a completion of Jun 2021. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2025, 4 years 4 months after primary completion. A results delay was requested in Jul 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2015
First posted
Jul 31, 2015
Start
Nov 2015
Primary completionActual
Jun 2021
CompletionActual
Jun 2021
Results delay requested
Jul 11, 2021
Results first posted
Oct 9, 2025
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02513303
Lead sponsor
Vascular Therapies, Inc.
Responsible party
Sponsor
First posted
Jul 31, 2015
Start date
Nov 2015
Primary completion
Jun 2021
Completion
Jun 2021
Results posted
Oct 9, 2025
Last update
Oct 9, 2025

Study contacts

Sriram Iyer, MD
study director · Vascular Therapies, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion